From: Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
Phase | Other agent | Disease (pt. No.) | Schedule | Recommended dose & response | Reference |
---|---|---|---|---|---|
I | Â | Advanced solid tumor(38) | Three times per week for 2 of every three weeks | 45 mg/m2/d | [113] |
I | Â | Relapsed or refractory AML (22), MDS (5), ALL(1) and CML (1) | Three times weekly without interruption | 60 mg/m2/d | [114] |
I/ | Gemcitabine | Solid tumor(24/I and 4/II) | Three times weekly for MGCD0103 and weeklyX3 for Gemcitabine in 28-days cycle | 90 mg/d and PR: 40% in 2 out of 5 pancreatic carcinoma. | [115] |
II | Â | Relapsed or refractory NHL(33 of DLBCL and 17 of FL) | Three times weekly without interruption | Started 110 mg, then decreased to 85 mg. RR for DLBCL 23.5% and PR for FL 10%. | [116] |
II | Â | Relapsed or refractory HL(33) | Three times weekly in 28 days cycle | 85 mg or 110 mg. OR 38%. | [117] |